Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Renal Cell 2Zollinger-Ellison Syndrome 1Uterine Cervical Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Melanoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gastrointestinal Cancer Metastatic 1Epstein-Barr Virus Infections 1Carcinoma, Hepatocellular 1Blast Crisis 1Adenoma, Islet Cell 1

Interventions

pazopanib 1YF 476 1Temozolomide 1Streptozocin 1Pantoprazole 1Omeprazole 1Interferons 1Fluorouracil 1Doxorubicin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Zollinger-Ellison Syndrome × Interferons × Clear all
NCT00001228 2017-07-02

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled

Adenoma, Islet Cell, Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡